Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-01-18
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Lion TCR Pte. Ltd.
- Target Recruit Count
- 55
- Registration Number
- NCT05195294
Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Lion TCR Pte. Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT04745403
- Locations
- 🇸🇬
Singapore General Hospital, Singapore, Singapore
A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Lion TCR Pte. Ltd.
- Registration Number
- NCT03634683
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
🇨🇳The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangzhou, China
🇨🇳The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangzhou, China
A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation
Phase 1
- Conditions
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Lion TCR Pte. Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT02719782
- Locations
- 🇨🇳
Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of TCR-Redirected T Cell Infusion to Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Lion TCR Pte. Ltd.
- Target Recruit Count
- 13
- Registration Number
- NCT02686372
- Locations
- 🇨🇳
The First Affiliated Hospital, Sun-Yat Sen University, Guangzhou, Guangdong, China
© Copyright 2024. All Rights Reserved by MedPath